HHS Launches Initiative To Curb Psychiatric Drug Overuse, Focus On Children
HHS Secretary Robert F. Kennedy Jr. on Monday, May 4, 2026 unveiled an initiative to curb the overuse of psychiatric medications, especially among children.[1]
The department sent a letter urging clinicians to prioritize informed consent, shared decision-making and routine reassessment while considering nondrug treatments. The Centers for Medicare and Medicaid Services issued guidance to reimburse physicians who help patients taper psychiatric drugs and monitor withdrawal. The plan also calls for a prescribing-trends report, extra clinician training and an expert panel to shape future policy.
The episode traces back to Kennedy's long-standing advocacy, including the 2011 founding of Children's Health Defense and his public criticism of psychiatric drugs. His views drew attention during an independent 2023 presidential campaign and a 2024 podcast remark about Black children on ADHD medication that drew intense criticism. After endorsing Donald Trump, Kennedy was confirmed as HHS secretary on January 29, 2025 and began pressing the issue publicly in February 2025. That push prompted pushback from medical groups and fed into an October 2025 controversy over substance abuse treatment; in February 2026 he launched a mental health and addiction initiative that committed $100 million to nondrug approaches. Use of SSRIs among U.S. children aged 3-17 rose from 1.5% in 2006 to 3.6% in 2023, and as of 2022 an estimated 11.4% of children aged 3-17 had ever been diagnosed with ADHD. Psychotropic medication use among youth aged 6-24 rose from 5.3% in 2001-2004 to 8.3% in 2017-March 2020.
Mainstream coverage has shifted from reporting Kennedy's skepticism to documenting concrete policy steps like reimbursement changes and a planned prescribing-trends report. Public reaction split online, ranging from praise as a needed check on drug makers to warnings from clinicians that limited access to care, not overprescribing, drives the problem.
The initiative to curb psychiatric drug overuse among children has sparked a range of reactions on social media. Health reporter @l_e_whyte highlights the measures aimed at assisting Americans in tapering off antidepressants, while others, like @Meidas_LaurenA, emphasize that the root of the crisis may lie in insufficient access to care rather than overprescribing. This sentiment is echoed by clinicians who argue that the focus should be on enhancing healthcare access rather than limiting prescriptions. Conversely, supporters like @AdamI1776 view the initiative as a necessary stand against pharmaceutical companies' influence, particularly regarding the overprescription of medications to children, framing it as a public health imperative.
Data from the U.S. Department of Health and Human Services indicates a troubling rise in psychiatric medication use among children, with SSRIs increasing from 1.5% in 2006 to 3.6% in 2023. Additionally, the CDC reports that 11.4% of children had been diagnosed with ADHD as of 2022. This context underscores the complexity of the issue, where rising mental health diagnoses and medication use intersect with calls for reform and better patient education on treatment options.
Show source details & analysis (2 sources)
📊 Relevant Data
From 2006 to 2023, the annual prevalence of U.S. children and adolescents aged 3-17 years receiving selective serotonin reuptake inhibitors (SSRIs) increased from 1.5% to 3.6%.
U.S. Population Prevalence of Prescription Psychiatric Medication Among Children and Adolescents — Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services
As of 2022, an estimated 11.4% of U.S. children aged 3–17 years (7.1 million children) have ever been diagnosed with ADHD.
Data and Statistics on ADHD — Centers for Disease Control and Prevention (CDC)
Psychotropic medication use among U.S. youth aged 6-24 increased from 5.3% in 2001-2004 to 8.3% in 2017-March 2020.
📌 Key Facts
- On Monday, May 4, 2026, HHS Secretary Robert F. Kennedy Jr. unveiled an initiative targeting what he described as overuse of psychiatric medications, particularly in children.
- HHS issued a letter urging clinicians to prioritize informed consent, shared decision-making, and routine reassessment of psychiatric medications while considering non-drug treatments.
- CMS announced new guidance allowing reimbursement for physicians who help patients safely taper off psychiatric medications and monitor withdrawal.
- The initiative includes a planned prescribing-trends report, additional clinician training, and an expert panel to inform future policy on psychiatric medication use.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- At a MAHA Institute event on Monday, May 4, 2026, HHS Secretary Robert F. Kennedy Jr. specifically announced a federal plan to help people wean off commonly used antidepressants such as Prozac, Zoloft, Lexapro and Paxil.
- Kennedy characterized the situation as a 'dependency crisis driven by overmedicalization' and said 'too many patients begin treatment without a clear understanding of the risks and how long they will stay on these drugs or how to come off of them.'
- An HHS 'Dear Colleague' letter to providers states that psychiatric medications can be essential and beneficial but stresses they should never be the only option and urges regular review of SSRI risks and shared decision-making about starting or tapering.
- The article reports that the Substance Abuse and Mental Health Services Administration will publish new data on prescribing trends and detailed clinical guidance on tapering in the coming months, while the Centers for Medicare and Medicaid Services will issue billing guidance so clinicians can be reimbursed for helping patients taper off antidepressants.
- American Psychiatric Association President Dr. Theresa Miskimen Rivera publicly called Kennedy’s framing an 'oversimplification' that ignores the major problem of poor access to comprehensive mental health care, while also saying APA supports better training and research on safe prescribing and tapering.